N
APLS

Natixis’s Apellis Pharmaceuticals APLS Stock Holding History

Natixis’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-257,268
Closed -$6.46M – 1111
2025
Q4 		$6.46M Buy
257,268
+205,029
+392% +$4.81M 0.02% 412
2025
Q3 		$1.18M Sell
52,239
-38,427
-42% -$896K 0.01% 648
2025
Q2 		$1.57M Sell
90,666
-564,361
-86% -$10.4M 0.01% 538
2025
Q1 		$14.8M Sell
655,027
-215,600
-25% -$5.96M 0.08% 178
2024
Q4 		$27.8M Buy
+870,627
New +$26.2M 0.17% 100
2024
Q2 		– Sell
-1,339
Closed -$78.7K – 993
2024
Q1 		$78.7K Sell
1,339
-90,719
-99% -$5.78M ﹤0.01% 796
2023
Q4 		$5.51M Buy
92,058
+83,558
+983% +$4.24M 0.04% 285
2023
Q3 		$323K Buy
+8,500
New +$373K ﹤0.01% 664
2023
Q2 		– Sell
-15,700
Closed -$1.04M – 1019
2023
Q1 		$1.04M Sell
15,700
-329,300
-95% -$19M 0.01% 516
2022
Q4 		$17.8M Buy
345,000
+63,000
+22% +$3.34M 0.1% 181
2022
Q3 		$19.3M Sell
282,000
-32,000
-10% -$1.89M 0.09% 171
2022
Q2 		$14.2M Buy
314,000
+45,900
+17% +$2.09M 0.05% 237
2022
Q1 		$13.6M Buy
+268,100
New +$11.8M 0.05% 341
2021
Q4 		– Sell
-216,500
Closed -$7.14M – 1218
2021
Q3 		$7.14M Buy
216,500
+107,300
+98% +$6.03M 0.02% 445
2021
Q2 		$6.9M Buy
+109,200
New +$5.63M 0.03% 333

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Natixis's APLS Position: Q1 2026 in Review

Natixis sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 257,268 shares — an estimated $6.46M sold.

Natixis first reported a position in APLS in Q2 2021 and held it in 15 quarters. The position peaked at $27.8M in Q4 2024. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Natixis reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Natixis sold 257,268 Apellis Pharmaceuticals shares in Q1 2026, an estimated $6.46M.
  • Natixis first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 15 quarters.
  • Natixis's Apellis Pharmaceuticals position peaked at $27.8M in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.